1. Asselin BL, Shuster J, Amylon MD, Halperin R, Lipshultz S, Camitta B (2001) Improved event-free survival (EFS) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and Advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group (POG) Study [Abstract 1464]. Proceedings of the American Society of Clinical Oncology 20
2. Bettachi CJ, Kamen BA, Cush JJ (1999) Post-methotrexate (MTX) CNS toxicity: symptom reduction with dextromethorphan. Arthritis Rheum 42:S236
3. Bleyer AW (1977) Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61:1419–1425
4. Capizzi RL (1981) Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells. Cancer Treat Rep 65(Suppl 4):115–121
5. Cole PD, Drachtman RA, Smith AK, Cate S, Larson RA, Hawkins DS, Holcenberg J, Kelly K, Kamen BA (2005) Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res 11:8089–8096